

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371</b>		ATTORNEY'S DOCKET NUMBER <b>BBC-166</b>
INTERNATIONAL APPLICATION NO. PCT/IB03/004502	INTERNATIONAL FILING DATE August 15, 2003	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>10/525292</b>
TITLE OF INVENTION <b>Formulation of Human Antibodies for Treating TNF-<math>\alpha</math> Associated Disorders</b>		PRIORITY DATE August 16, 2002
APPLICANT(S) FOR DO/EO/US <b>Hans-Juergen Krause et al.</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> <li>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</li> </ol>		
<b>Items 11 to 20 below concern document(s) or information</b>		
<ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input checked="" type="checkbox"/> A preliminary amendment.</li> <li>14. <input type="checkbox"/> An application Data Sheet under 37 CFR 1.76.</li> <li>15. <input type="checkbox"/> A substitute specification.</li> <li>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</li> <li>17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</li> <li>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</li> <li>19. <input type="checkbox"/> A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).</li> <li>20. <input checked="" type="checkbox"/> Other items or information: <div style="margin-left: 20px;"> Combined Declaration for a Patent Application and Power of Attorney (unsigned), Transmittal of Sequence Listing, Computer Readable Form and Amendment pertaining thereto for Invention Containing Nucléotide and/or Amino Acid Sequence Under 37 CFR §§1.821-1.825, Paper Copy of Sequence Listing, Response to the Written Opinion Under Rule 66 PCT, Return Receipt Postcard </div> </li> </ol>		

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.53) <b>10/525292</b>		INTERNATIONAL APPLICATION NO. <b>PCT/IB03/004502</b>		ATTORNEY'S DOCKET NUMBER <b>BBC-166</b>	
21. The following fees are submitted:				Applicant use	Office use only
<input checked="" type="checkbox"/> a) Basic national fee .....		\$300.00		\$	\$300.00
<input checked="" type="checkbox"/> b) Examination fee .....		\$200.00		\$	\$200.00
<input checked="" type="checkbox"/> c) Search fee .....		\$500.00		\$	\$500.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>		<b>\$1000.00</b>		\$	<b>\$1,000.00</b>
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole)	RATE		
36 - 100 =	-64 /50 =	-1	x	\$	\$0.00
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	23 - 20 =	3	x \$50.00	\$	\$150.00
Independent claims	3 - 3 =	0	x \$200.00	\$	\$0.00
Multiple Dependent Claims (if applicable) <input type="checkbox"/>			+ \$360.00	\$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$	<b>\$1,150.00</b>
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	\$0.00
<b>SUBTOTAL =</b>				\$	<b>\$1,150.00</b>
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	\$
<b>TOTAL NATIONAL FEE =</b>				\$	<b>\$1,150.00</b>
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per				+	\$
<b>TOTAL FEES ENCLOSED =</b>				\$	<b>\$1,150.00</b>
<b>Amount to be refunded:</b>					\$
<b>Amount to be charged:</b>					\$
<p>a. <input type="checkbox"/> A check in the amount of _____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account <u>01-0025</u> in the amount of <u>\$1,150.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account <u>01-0025</u>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>					
<p><b>NOTE:</b> Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.</p>					
SEND ALL CORRESPONDENCE TO:					
<p>John D. Conway Abbott Bioresearch Center 100 Research Drive Worcester, MA 01605-4314</p>					
				 SIGNATURE	
				<p>John D. Conway</p> NAME	
				<p>39,150</p> REGISTRATION NUMBER	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Hans-Juergen Krause et al.	
PCT Application No.	PCT/IB2003/004502	
PCT Filing Date:	15 August 2003	ART UNIT: (not yet assigned)
U.S. Serial No.:	(not yet assigned)	
Filed:	(concurrently herewith)	EXAMINER: (not yet assigned)
Priority Date:	16 August 2002	
Entitled:	FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF- $\alpha$ ASSOCIATED DISORDERS	


Attorney Docket No.: BBC-166

**Mail Stop PCT**  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

**PATENT APPLICATION TRANSMITTAL - SUBMISSION UNDER 35 U.S.C. 371**

1. Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Submission Under 35 U.S.C. 371 form PTO/1390 (in duplicate), including authorization to charge Deposit Account the amount of \$ 1,150.00 to cover the application filing fees.
2. Copy of application specification of 36 pages (including Abstract of the Disclosure).
3. Preliminary Amendment
4. Combined Declaration for a Patent Application and Power of Attorney (unsigned).
5. Transmittal of Sequence Listing, Computer Readable Form and Amendment pertaining thereto for Invention Containing Nucleotide and/or Amino Acid Sequence Under 37 CFR §§1.821-1.825
6. Paper copy of Sequence Listing (8 Pages)
7. Diskette containing a computer readable form (CRF) copy of the sequence Listing
8. Response to Written Opinion Under Rule 66 PCT
9. Return receipt post card.


Respectfully submitted,

  
 John D. Conway  
 Registration No. 39,150  
 Attorney for Applicant  
 ABBOTT BIORESEARCH CENTER  
 100 Research Drive  
 Worcester, Massachusetts 01605-4314  
 telephone: (508) 688-8046  
 telefax: (508) 688-8110

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

The undersigned hereby certifies that this correspondence listed above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, Express Mailing Label No. ED072003559US, in an envelope addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

February 16, 2005  
 Date

  
 Lisa Rasmussen